Daniel Batey
Research Subjects
Daniel Batey has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Marie-Liesse Asselin-Labat
Walter and Eliza Hall Institute of Medical Research
14 shared publications - Adithya Balasubramanian
Walter and Eliza Hall Institute of Medical Research 6
12 shared publications - Ashray Gunjur
Wellcome Sanger Institute, Hinxton, United Kingdom
12 shared publications - Belinda Phipson
Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
12 shared publications - Claire Marceaux
The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
12 shared publications - Clare Senko
La Trobe University School of Cancer Medicine, Olivia Newton-John Cancer Research Institute, Melbourne, Australia
12 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (12)
Mapping lung cancer ventilation dynamics using functional imaging and lung mechanics
In vivo models that replicate and reproduce human lung cancer and its response to therapy are necessary for the development of new therapeutic strategies and understanding drug resistance. Imaging lung tumors in live animals to monitor tumor growth and response to therapy is challenging owing to the location of the lungs and their constant movement during breathing. X-ray velocimetry (XV) is a novel functional lung imaging technique that maps regional lung expansion during breathing, providing spatial information on where ventilation changes occur. The aim of this pilot study was to use XV and flexiVent lung mechanics assessments to determine the effect of tumor growth on lung function in mice at 2 or 3 weeks post tumor induction and to evaluate the efficacy of these two tools. Histological analysis showed that tumor growth was not uniform between animals. At 3 weeks post tumor induction, some XV ventilation and flexiVent lung mechanics parameters were significantly different from baseline. Both techniques gave metrics that correlated with the tumor counts from the histology. In some mice, XV revealed localized regions with altered expansion rates.
- 1 December 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (12)
Open AccessMapping lung cancer ventilation dynamics using functional imaging and lung mechanics
In vivo models that replicate and reproduce human lung cancer and its response to therapy are necessary for the development of new therapeutic strategies and understanding drug resistance. Imaging lung tumors in live animals to monitor tumor growth and response to therapy is challenging owing to the location of the lungs and their constant movement during breathing. X-ray velocimetry (XV) is a novel functional lung imaging technique that maps regional lung expansion during breathing, providing spatial information on where ventilation changes occur. The aim of this pilot study was to use XV and flexiVent lung mechanics assessments to determine the effect of tumor growth on lung function in mice at 2 or 3 weeks post tumor induction and to evaluate the efficacy of these two tools. Histological analysis showed that tumor growth was not uniform between animals. At 3 weeks post tumor induction, some XV ventilation and flexiVent lung mechanics parameters were significantly different from baseline. Both techniques gave metrics that correlated with the tumor counts from the histology. In some mice, XV revealed localized regions with altered expansion rates.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 4. Analysis of immune cell populations in gPFS and loPFS samples.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 4. Analysis of immune cell populations in gPFS and loPFS samples.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 2. Representativeness of study participants
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 2. Representativeness of study participants
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 2. Tumor cell characteristics at baseline and on treatment in gPFS and loPFS patients
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 2. Tumor cell characteristics at baseline and on treatment in gPFS and loPFS patients
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 1. CAVATAK trial inclusion and exclusion criterias
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 1. CAVATAK trial inclusion and exclusion criterias
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 1. Survival analysis.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 1. Survival analysis.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 4: Systemic therapy received by each patient prior to recruitment into the trial.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 4: Systemic therapy received by each patient prior to recruitment into the trial.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 3. Analysis of immune cell populations in all samples
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 3. Analysis of immune cell populations in all samples
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 3: Antibodies used in the MIBI panel.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 3: Antibodies used in the MIBI panel.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 5. Functional markers expressed in CD8+ T cells in gPFS patients
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 5. Functional markers expressed in CD8+ T cells in gPFS patients